Pyridine derivative
The present invention relates to a novel pyridine derivative or a pharmacologically acceptable ester thereof, or a pharmacologically acceptable salt of the derivative or ester, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ. A compound represented by the general formula (I): [wherein R represents a pyridyl group substituted with 1 to 3 group(s) independently selected from Substituent Group A, and Substituent Group A represents a halogen atom, a C 1 -C 6 alkyl group and a C 1 -C 6 alkoxy group] or a pharmacologically acceptable ester thereof, or a pharmacologically acceptable salt of the compound or ester.
1. A compound having a formula (I):
or a pharmacologically acceptable C 1 to C 4 alkyl ester of the compound, or a pharmacologically acceptable salt of the compound or the ester.
2. The compound according to claim 1 that is: 3-({6-[(3,5-dimethylpyridin-2-yl)oxy]-1-methyl-1H-benzimidazol-2-yl}methoxy)benzoic acid.
3. The compound according to claim 1 that is: a pharmacologically acceptable salt of 3-({6-[(3,5-dimethylpyridin-2-yl)oxy]-1-methyl-1H-benzimidazol-2-yl}methoxy)benzoic acid.
4. The compound according to claim 1 that is: a calcium salt of 3-({6-[(3,5-dimethylpyridin-2-yl)oxy]-1-methyl-1H-benzimidazol-2-yl}methoxy)benzoic acid.
5. The compound according to claim 1 that is: a sodium salt of 3-({6-[(3,5-dimethylpyridin-2-yl)oxy]-1-methyl-1H-benzimidazol-2-yl}methoxy)benzoic acid.
6. The compound according to claim 1 that is: a hydrochloride salt of 3-({6-[(3,5-dimethylpyridin-2-yl)oxy]-1-methyl-1H-benzimidazol-2-yl}methoxy)benzoic acid.
7. A composition comprising the compound, or the pharmacologically acceptable C 1 to C 4 alkyl ester of the compound, or the pharmacologically acceptable salt of the compound or the ester of claim 1 and an inert carrier or diluent.
8. The composition according to claim 7 , further comprising an additive.
9. The composition according to claim 8 , wherein the additive is selected from the group consisting of: excipients, lubricants, binders, disintegrants, stabilizers, corrigents, diluents, and a combination thereof.
10. The composition according to claim 7 , wherein the composition is for oral administration.
11. A method for the treatment of a disease selected from the group consisting of: diabetes, type II diabetes, impaired glucose tolerance, and gestational diabetes mellitus, the method comprising
administering a pharmacologically effective amount of the compound, or the pharmacologically acceptable ester of the compound, or the pharmacologically acceptable salt of the compound or the ester of claim 1 to a warm-blooded animal.
12. The method according to claim 11 , wherein the warm-blooded animal is a human.
13. The method according to claim 12 , wherein the disease is diabetes.
14. The method according to claim 12 , wherein the disease is type II diabetes.
15. A method for lowering blood glucose levels in a human comprising
administering a pharmacologically effective amount of the compound, or the pharmacologically acceptable ester of the compound, or the pharmacologically acceptable salt of the compound or the ester of claim 1 to the human.
16. A method for improving insulin resistance in a human comprising
administering a pharmacologically effective amount of the compound, or the pharmacologically acceptable ester of the compound, or the pharmacologically acceptable salt of the compound or the ester of claim 1 to the human.
17. A method for activating peroxisome proliferator-activated receptor (PPAR) γ in a human, comprising
administering a pharmacologically effective amount of the compound, or the pharmacologically acceptable ester of the compound, or the pharmacologically acceptable salt of the compound or the ester of claim 1 to the human.